Aldeyra Therapeutics, Inc.

Disclaimer : Sections of this page are auto-generated by Artificial Intelligence and shall not be understood as Investment Advice

This page was updated : N/A. Premium customers can update this page on demand.

Invite a Friend

Newsflash

N/A

Based on these articles

Business Overview

N/A

Yahoo - Business Overview

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer, ...

Website

#adx #aldeyra #rasp #therapeutics #modulator #mediated #diseases #immune #treatment #vitreoretinopathy #United States #Healthcare

Risk Rating (Yahoo)

None

ESG Score (Yahoo)

N/A

Market Cap (USD)

545 M

AI Rank (finclout)

582

Competitors

Flags & Key Risks

No Revenue Negative Return on Equity Negative Debt Trend Negative profit margins Negative EV to Ebitda

Themes

Biotechnology Medicines Clinical trial RASP modulator Immune-mediated diseases

SWOT Analysis Disclaimer : This is generated by AI, may contain errors, and shall not be understood as investment advice in any way.

Strengths

N/A

Weaknesses

N/A

Opportunities

N/A

Threats

N/A

Thesis for Aldeyra Therapeutics, Inc.

Disclaimer : This is generated by AI, may contain errors, and shall not be understood as investment advice in any way.

Bullish

N/A ...

Neutral

N/ ... A

Bearish

N/ ... A

News Coverage

24 days ago @Seeking Alpha Buy Aldeyra Therapeutics For Consecutive Runups	#Seeking Alpha #ALDX #clinically-sound-investor #investing-ideas #long-ideas #event-special-situations #drug-approval
26 days ago @Business Wire Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights	#Business Wire #ALDX #earnings #aldeyra #mediated #immune #diseases

23 days ago @semodough $ALDX two forthcoming PDUFA dates June 21, 2023, for non-compounded intravitreal methotrexate candidate ADX-2191, i… https://t.co/rcM5IgE6NY	#semodough #ALDX #forthcoming #pdufa #aldx #compounded #candidate
26 days ago @biostocks $ALDX https://t.co/Sw7NQR1S0w	#biostocks #ALDX #aldx #ALDX
26 days ago @FlashAlert_me $ALDX [15s. delayed] filed form 8-K on May 04, 07:05:27 https://t.co/OeIaAedb2d	#FlashAlert_me #ALDX #aldx #filed #delayed #form #co
1 month ago @biostocks $ALDX Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis Topline Data 1H'23	#biostocks #ALDX #invigorate #conjunctivitis #allergic #topline #aldx
1 month ago @FlashAlert_me $ALDX [15s. delayed]: Issued Press Release on April 13, 07:00:00: Aldeyra Therapeutics Completes Enrollment in Phas… https://t.co/YYQciBkPAR	#FlashAlert_me #ALDX #yyqcibkparflashalert_me #phas #aldeyra #aldx #completes
2 months ago @biostocks $ALDX Completes Enrollment in Phase 2 Clinical Trial of ADX‑2191 in Retinitis Pigmentosa. Top-Line Data 1H'23	#biostocks #ALDX #retinitis #pigmentosa #aldx #completes #enrollment
2 months ago @biostocks $ALDX -Topline Data from Phase 3 INVIGORATE-2 Trial of Reproxalap in Allergic Conjunctivitis in 1H'23 -Topline Dat… https://t.co/bysWOtfSRj	#biostocks #ALDX #topline #byswotfsrjbiostocks #reproxalap #invigorate #conjunctivitis